 |
We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.
source: Antengene Corporation Limited
【你點睇？】80歲的士司機撞斃遊客，報稱駕駛時頭暈，你認為當局應否立法設商業司機強制退休年齡？► 立即投票
